ESMC 最新10-K变化

相对上期新增的文字 · 来源:10-K · 2026-10-13

• other procedures. If the FDA finds any deficiencies the FDA may impose restrictions on marketing the specific products until such deficiencies are corrected.

• The Company seeks to protect its proprietary technologies, products and processes through a combination of patents, trademarks, trade secrets, confidentiality agreements, and other intellectual property protections, as appropriate. While the Company maintains patent protection for certain aspects of…

相对上期删除的文字 · 来源:10-K · 2025-09-29

• The pharmaceutical and medical device communities place considerable importance on obtaining patent and trade secret protection for new technologies, products and processes for the purpose of strengthening the Company’s position in the market place and protecting the Company’s economic interests. Th…

相对上期新增的文字 · 来源:10-K · 2026-10-13

• The Company has identified a material weakness in its internal control over financial reporting, which could result in material misstatements in the Company’s financial statements.

• As disclosed in Item 9A of this Annual Report, management identified a material weakness in the Company’s internal control over financial reporting that existed as of June 30, 2026. The material weakness relates to the design and implementation of controls over estimates used in the valuation of inv…

• been remediated. Beginning in the fourth quarter of fiscal 2024 and continuing through fiscal 2025 and 2026, management implemented additional controls, including a standardized process for updating standard costs, enhanced segregation of duties over updates and reviews, improved data accuracy and i…

• A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. Al…

• If the Company is unable to remediate the material weakness, or if additional material weaknesses or significant deficiencies are identified in the future, the Company’s ability to report its financial results on a timely and accurate basis

相对上期删除的文字 · 来源:10-K · 2025-09-29

• In addition to other information contained in this report on Form 10-K, the following Risk Factors should be considered carefully in evaluating our business. If any of the following risks actually occur, our financial condition and results of operations could be materially and adversely affected.

• Due to the Company’s history of operating losses, we have compiled these financial statements based on the assumption there is substantial doubt related to our ability to continued as a going concern.

• As of June 30, 2025, we had an accumulated deficit of $68.4 million, and had incurred historical recurring losses from operations and negative cash flows from operating activities in prior years except for the fiscal year ended June 30, 2023 and 2025. While the overall trend has been toward profitab…

• As a result of above matters, our independent auditors have indicated in their report on our June 30, 2025 financial statements that there is substantial doubt about our ability to continue as a going concern. A "going concern" opinion indicates that the financial statements have been prepared assum…

• Our continued operations will ultimately depend on the ability to be profitable from our operations and the ongoing support of our stockholders and creditors.

相对上期新增的文字 · 来源:10-K · 2026-10-13

• •Consolidated research and development expenses decreased $252,000 or 33.5%, to $501,000 during the year ended June 30, 2026, as compared to the same period of the prior fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced product…

• •During the year ended June 30, 2026, the Company sold its AXIS software for an aggregate purchase price of $3,000,000. The Company received net proceeds of $2,800,000 and recognized a gain of $2,813,525, before income taxes, on the sale.

• •The Company released $1,139,449 of its valuation allowance related to previously fully reserved deferred tax assets after evaluating the positive and negative evidence, and consequently recognized a corresponding deferred income tax benefit in the consolidated statement of operations for the fiscal…

• The following table shows consolidated net revenue, as well as identifying trends in revenues for the years ended June 30, 2026 and 2025. Table amounts are in thousands:

• Consolidated net revenue increased approximately $690,000 or 5.7%, to $12,736,000 during the year ended June 30, 2026,as compared to the prior fiscal year. The increase in net revenue is mainly attributable to a $1,259,000 increase in sales of Sonomed products and services, partially offset by a $51…

相对上期删除的文字 · 来源:10-K · 2025-09-29

• •Consolidated research and development expenses increased $65,000 or 9.4%, to $753,000 during the year ended June 30, 2025 as compared to the same period of the prior fiscal year. Research and development expenses were

• primarily expenses associated with the introduction of new or enhanced products. The increase in research and development expense is mainly due to increased AXIS consulting expenses during the year ended June 30, 2025.

• The following table shows consolidated net revenue, as well as identifying trends in revenues for the years ended June 30, 2025 and 2024. Table amounts are in thousands:

• Consolidated net revenue increased approximately $64,000 or 0.5%, to $12,046,000 during the year ended June 30, 2025 as compared to the prior fiscal year. The increase in net revenue is mainly attributed to an increase of approximately $114,000 in sales of Trek products, offset by a decrease of $33,…

• The following table presents consolidated research and development expenses for the years ended June 30, 2025 and 2024.